Newsmeme!
Discover News you didn't know existed
More than 200 abstracts from therapies across the Novartis Oncology portfolio will be presented at two December medical congresses, providing new data and profiling potential patient benefits from ongoing collaboration with the oncology community.
Tasigna front-line data demonstrating potential in newly diagnosed patients with a life-threatening type of leukemia to be featured in two oral sessions at ASH
HemoGenix® and ORF Genetics announce the collaboration and implementation of biorisk-free, green-source growth factors and cytokines for use in all HALO® Assay Kits and HALO® Contract Research Services where the response of human blood-forming cells is detected.
The Food and Drug Administration issued a conclusion on Nov. 28 concerning the safety and relative toxicity of melamine in baby formula, claiming that 1 part per million can cause no real harm. This study is a response to the September outcry over China's use of the substance in dairy products, which caused thousands of infants to fall sick and at least four to die, in addition to the cats and ...
Vical Incorporated today announced an exclusive, binding letter of intent with EIP Eczacibasi Ilac Pazarlama A.S. for sales and marketing of the company's Allovectin-7® immunotherapeutic product candidate in Turkey and the Turkish Republic of Northern Cyprus.
Horizon Therapeutics, Inc., a privately held biopharmaceutical company, announced that two pivotal Phase 3 trials evaluating its lead investigational product candidate, HZT-501, met all primary endpoints.
Horizon Therapeutics, Inc. has announced that two pivotal Phase 3 trials evaluating its lead investigational product candidate, HZT 501, met all primary endpoints.
( WeissComm Partners ) Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today announced that two pivotal Phase 3 trials evaluating its lead investigational product candidate, HZT 501, met all primary endpoints. HZT 501, a novel, proprietary fixed-dose combination product containing ibuprofen and famotidine, demonstrated a statistically significant reduction in the ...
Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today announced that two pivotal Phase 3 trials evaluating its lead investigational product candidate, HZT-501, met all primary endpoints.
Chemoradiotherapy (CRT) can be considered an "effective" treatment for elderly patients with locally advanced oesophageal cancer, reports the British Journal of Cancer.
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |